Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning.

Trial Profile

Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Depressive disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Dec 2015 According to ClinicalTrials.gov record, the treatment table has been amended to include 2 arms.
    • 30 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.
    • 04 Jun 2015 Planned End Date changed from 1 Jan 2013 to 1 Dec 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top